| abstract |
The present invention relates to the compounds of the formula (I): (see Formula) wherein Y, Y1, R1, R2, R3 and R4 are defined in the Brief Description of the Invention; capable of inhibiting the activity of BCR-ABL1 and the mutants thereof. The invention further provides a process for the preparation of the compounds of the invention, the pharmaceutical preparations comprising these compounds, and the methods for using such compounds in the treatment of cancers. |